bluebird bio Inc (NASDAQ:BLUE) announced that interim data from its ongoing Phase 1 clinical study of bb2121, the company’s investigational anti-BCMA CAR T cell …
Yesterday, Piper Jaffray analyst Joshua Schimmer hosted an investor dinner with bluebird bio Inc (NASDAQ:BLUE) management ahead of his healthcare conference. Following the …
News from Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) and bluebird bio Inc (NASDAQ:BLUE) have sent biotech investors running for the hills and have left shares …
bluebird bio Inc (NASDAQ:BLUE) reported business highlights and financial results for the third quarter ended September 30, 2016. “In recent months, we have …
On October 13th, bluebird bio Inc (NASDAQ:BLUE) hosted a Research and Development (R&D) Day shining light on its newly implemented process and manufacturing …
Following bluebird bio Inc’s (NASDAQ:BLUE) first research and development (R&D) meeting, Cowen top analyst Eric Schmidt shares insight on the firm’s preclinical strides …
bluebird bio Inc (NASDAQ:BLUE) will outline today key activities underway intended to advance the company’s LentiGlobin programs in transfusion-dependent β-thalassemia (TDT) and severe …
Maxim analyst Jason McCarthy is out with a research report on shares of bluebird bio Inc (NASDAQ:BLUE) discussing the aftermath of Mast Therapeutics’ (NYSEMKT:MSTX) …
bluebird bio Inc (NASDAQ:BLUE) announced the signing of a strategic research and development collaboration and licensing agreement encompassing T cell receptor (TCR) immunotherapies …
Jefferies analysts are diving into the latest biotech news, with Gilead Sciences, Inc. (NASDAQ:GILD) and bluebird bio Inc (NASDAQ:BLUE) on opposite ends of the spectrum.
